Company Encyclopedia
View More
name
Agios Pharmac
AGIO.US
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company’s PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it develops tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and hemolytic anemias; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera.
1.946 T
AGIO.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking94/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-27.57%E
    • Profit Margin-895.86%E
    • Gross Margin-586.92%E
  • Growth ScoreC
    • Revenue YoY36.26%A
    • Net Profit YoY-159.51%E
    • Total Assets YoY-22.66%E
    • Net Assets YoY-21.05%E
  • Cash ScoreB
    • Cash Flow Margin-11.16%D
    • OCF YoY36.26%A
  • Operating ScoreE
    • Turnover0.03E
  • Debt ScoreA
    • Gearing Ratio7.32%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Why Agios Pharmaceuticals (AGIO) Is Down 7.1% After Phase 3 Sickle Cell Win With Mitapivat

    Agios Pharmaceuticals reported positive Phase 3 RISE UP trial results for mitapivat in sickle cell disease, showing significant hemoglobin improvement. Despite this success, the stock fell 7.1% due to concerns over high R&D and SG&A expenses, which may keep the company loss-making in the near term. The upcoming FDA decision on mitapivat for thalassemia is also crucial. Agios projects $416.9 million revenue and $67.0 million earnings by 2028, with a fair value estimate of $42.33 per share, a 57% upside from the current price.

    Simplywall·
    US
    AGIO
    -0.25%
    Simplywall·
    US
    AGIO
    -0.25%

    Agios Pharmaceuticals (NASDAQ:AGIO) Given New $20.00 Price Target at JPMorgan Chase & Co.

    JPMorgan Chase & Co. lowered Agios Pharmaceuticals' price target from $37.00 to $20.00, maintaining a "neutral" rating. Other firms also adjusted their targets, with mixed ratings ranging from "buy" to "sector perform." The stock's average rating is "Moderate Buy" with a $36.00 target. Agios reported better-than-expected quarterly earnings, with revenue up 43.3% year-over-year. Insider sales and hedge fund activities were noted, with 4.30% insider ownership.

    Market Beat·
    US
    AGIO
    -0.25%
    Market Beat·
    US
    AGIO
    -0.25%

    Agios Pharmaceuticals (NASDAQ:AGIO) Raised to Strong-Buy at Leerink Partnrs

    Leerink Partnrs upgraded Agios Pharmaceuticals (NASDAQ:AGIO) from a "hold" to a "strong-buy" rating. Other analysts have mixed ratings, with some downgrading their price targets. The stock opened at $24.57, with a market cap of $1.43 billion. Recent insider sales and institutional inflows were noted. Agios reported a quarterly EPS of ($1.78), beating estimates, with revenue up 43.3% year-over-year.

    Market Beat·
    US
    AGIO
    -0.25%
    Market Beat·
    US
    AGIO
    -0.25%

    Agios Pharmaceuticals shares are trading higher after Leerink Partners upgraded the stock from Market Perform to Outperform. The stock may also be rebounding after falling Wednesday on Phase 3 RISE UP trial data.

    benzinga_article·
    US
    AGIO
    -0.25%
    benzinga_article·
    US
    AGIO
    -0.25%

    A Look at Agios Pharmaceuticals's Valuation After Mixed Results From RISE UP Mitapivat Trial (AGIO)

    Agios Pharmaceuticals' Phase 3 RISE UP trial for mitapivat in sickle cell disease met its primary endpoint but missed a key secondary goal, leading to a 48% drop in share price this week. Despite mixed trial results, some analysts view the company as undervalued, with a fair value estimate of $42.33, compared to the current price of $22.34. However, high R&D costs and valuation risks remain concerns. The potential FDA approval of PYRUKYND for thalassemia could expand Agios' market.

    Simplywall·
    US
    AGIO
    -0.25%
    Simplywall·
    US
    AGIO
    -0.25%
    © 2025 Longbridge｜Disclaimer